• ISSN: 2349-6002
  • UGC Approved Journal No 47859
Author Login IJIRT Partner Network (IPN) Login

Target delivery of remdesivir may minimize the hepatotoxicity in COVID-19

  • Unique Paper ID: 153852
  • Volume: 8
  • Issue: 9
  • PageNo: 97-99
  • Abstract:
  • Remdesivir is a broad-spectrum antiviral agent meant to inhibit viral RNA polymerases against members of several virus families, including filoviruses. Although reported for significant clinical improvements in COVID-19, a detailed observation of the connection with the drawbacks of remdesivir therapy was poor pulmonary distribution and hepatotoxicity (transaminase elevation) was recorded that resulted in discontinuation of remdesivir therapy. Nanodrug delivery facilitates a large drug payload to the targeted site improving the efficacy. With the lesser dose administered, could be expected for minimized adverse events. Additional payload of ashwagandha will protect the liver from the damages caused if any. Remdesivir may be a safe and an effective therapeutic agent for COVID 19 when co-administered with ashwagandha as nanoparticles
Download article email to a friend

Cite This Article

  • ISSN: 2349-6002
  • Volume: 8
  • Issue: 9
  • PageNo: 97-99

Target delivery of remdesivir may minimize the hepatotoxicity in COVID-19

Related Articles

18 May, 2023

FORMULATION AND EVALUATION OF LISINOPRIL AS FAST DISSOLVING TABLET

Read More
Impact Factor
8.01 (Year 2024)
UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Archive

View More

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry